ClinicalTrials.gg
Status unknownNCT03527888Updated May 21, 2019

Study of Anlotinib in Patients With Primary Malignant Bone Tumors

A Phase 2 interventional study of Anlotinib in Neoplasm of Bone, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 6 sites in China. Open to participants aged 14 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-05-21.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2019), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
14 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Bone Neoplasms with a site in China — 13 open to participants now, 13 under way, none of them phase 3. Bone Neoplasms · China.

Enrollment
7th of 17
40 · median 32
Started
2018
with 2 others
Phase 2
Only one
of the 24
Registered
4th of 24
by date
Lead sponsor
1 of 24
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 24 studies in Bone Neoplasms with a site in China, this one is the 7th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2018, is the only one in phase 2, and was the 4th registered.

Bone Neoplasms

259 studies on the registry are indexed under Bone Neoplasms; 69 are open to participants now.

Browse Bone Neoplasms studies →

Open to participants now

13 of the 24 studies in Bone Neoplasms with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 53 Bone Neoplasms studies recruiting now, 34 (64%) set no upper age limit and 13 (25%) stop at 75 or younger; 24 take children under 18; 4 take healthy volunteers.

This study: 14 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Bone Neoplasms with a site in China, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of patients with recurrent and metastatic bone tumors.

03

Conditions studied

  • Neoplasm of Bone

Browse trials for

04

Who can participate

Ages eligible
14 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient volunteered to participate in this study and signed an ;
  2. Pathological diagnosis of osteosarcoma, chondrosarcoma, source of undifferentiated pleomorphic sarcoma / malignant fibrous histiocytoma, derived bone giant cell tumor of bone or bone primary Ewing's sarcoma / primitive neuroectodermal tumor (PNET) tumor;
  3. All patients were failed in chemotherapy (including anthracycline) or intolerance, recurrence or distant , and at least one (according to 1.1 criteria);
  4. At the age of 14-70, less than 18 year old patients with body surface area to more than 1.5m2;
  5. PS score: 0\~1 score (amputation patient's PS score is 0\~2), and the expected survival time is over March;
  6. The main organs function within 7 days before the treatment, in accordance with the following criteria: the standard of blood routine examination (in 14 days without blood transfusion): The is greater than or equal to 90g/L (by multiple tumor metastasis induced anemia, hemoglobin = 85g/L); The neutrophil absolute value is more than 1.5 * 109/L; over 80 * 109/L. biochemical examination should comply with the following criteria: The total is less than or equal to 1.5 Long ; The and aspartate aminotransferase is less than or equal to 2.5ULN, such as liver metastasis, ALT and AST = 5ULN; The serum creatinine or rate is greater than 1.5ULN 60ml/min; Doppler ultrasound assessment of the lower limit of normal value is more than the (50%).
  7. Women of childbearing age should use measures must be agreed within 6 months in the study period and after the end of the study (such as IUD, pill or condoms); in the study before entering the group within 7 days of serum or urine pregnancy test is negative, and must be for patients with non lactation; men should agree to use contraceptive measures must be 6 months in the research period and the end of the study period after the patients.

Exclusion criteria

Exclusion Criteria:

  • Patients with immunodeficiency, including positive or other acquired, congenital immunodeficiency disease, or organ transplant history Hypertension (systolic BP ≥150 mmHg, diastolic BP ≥90 mmHg) still uncontrollable by one medication virus patients with active replication (DNA> 500 cps / mL),
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Other
    Anlotinib

    Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

    Drug: Anlotinib

Interventions

  • Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

06

What researchers measure

Primary outcomes

  1. Progress free survival (PFS)

    From random grouping to the objective progression or death of a tumor

    Time frame: through study completion, an average of 6 month

Secondary outcomes

  1. Overall Survival (OS)

    The time in which the group begins to cause death for any reason

    Time frame: through study completion, an average of 10 month

07

Study locations

6 sites
  • Beijing Jishuitan Hospital
    Beijing, Beijing 100035, China
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
  • Shanghai No.6 People's Hospital
    Shanghai, Shanghai 200233, China
  • The First Affiliated Hospital of the Air Force Medical University
    Xi'an, Shanxi 710032, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2018 (actual). Primary completion is estimated for Dec 2019, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2018
First posted
May 17, 2018
StartActual
Jan 31, 2018
Primary completionEst.
Dec 31, 2019
CompletionEst.
Dec 31, 2019
Last update
May 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03527888
Responsible party
Sponsor
First posted
May 17, 2018
Start date
Jan 31, 2018
Primary completion
Dec 31, 2019 (estimated)
Completion
Dec 31, 2019 (estimated)
Last update
May 21, 2019

Study contacts

Yang Yao
principal investigator · Shanghai 6th People's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anlotinib

Start the discussion